Sugi Predict

Sugi Predict / Compounds / SCHEMBL1551972

SCHEMBL1551972

SCHEMBL1551972

N=C(N)NCCC[C@H](N)C(=O)Oc1ccc(C[C@H](N)C(=O)O)cc1

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 3/20 0.47
▸ ITGB3 P05106 1/20 0.45
▸ ITGA2B P08514 1/20 0.45
▸ NPY4R P50391 9/20 0.44
▸ NPY1R P25929 6/20 0.44
▸ PTPN1 P18031 1/20 0.43
▸ NPY2R P49146 4/20 0.42
▸ NPY5R Q15761 4/20 0.42
▸ ALPI P09923 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ PTGS1 P23219 1/20 0.41
▸ XIAP P98170 1/20 0.41
▸ TPH1 P17752 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1231526 0.99 SLC7A5 (0.47) SLC7A5ITGB3ITGA2BNPY4RNPY1R
Glycine SCHEMBL5579222 0.96 ITGB3 (0.45) SLC7A5ITGB3ITGA2BNPY4RNPY1R
Arginine SCHEMBL10610679 0.94 ITGB3 (0.51) SLC7A5ITGB3ITGA2BNPY4RNPY1R
Leucine SCHEMBL8853541 0.93 NPY4R (0.50) SLC7A5ITGB3ITGA2BNPY4RNPY1R
Arginine SCHEMBL4843979 0.91 NPY4R (0.47) SLC7A5ITGB3ITGA2BNPY4RNPY1R
Arginine SCHEMBL11382644 0.89 ITGB3 (0.48) SLC7A5ITGB3ITGA2BNPY4RNPY1R
Aspartic Acid SCHEMBL10457651 0.88 SLC7A5 (0.39) SLC7A5ITGB3ITGA2BNPY4RNPY1R
Histidine SCHEMBL2330373 0.88 SLC7A5 (0.41) SLC7A5ITGB3ITGA2BNPY4RNPY1R
Arginine SCHEMBL6808147 0.87 NPY4R (0.45) SLC7A5ITGB3ITGA2BNPY4RNPY1R
Arginine SCHEMBL9540783 0.87 ITGB3 (0.48) SLC7A5ITGB3ITGA2BNPY4RNPY1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1283657-C Novel chromogenic substances and use thereof for the determination of carboxypeptidase activities STAGO DIAGNOSTICA (FR) 2006-11-08 — — CN claimed
CN-1524087-A Novel chromogenic substances and use thereof for the determination of carboxypeptidase activities — 2004-08-25 — — CN claimed
CN-115969729-A Clathrate compound of acetyl dipeptide-1 cetyl ester and preparation method thereof 深圳市迪克曼生物科技有限公司 2023-04-18 — — CN disclosed
US-20190083407-A1 CRYSTALLIZATION METHOD AND BIOAVAILABILITY GRUNENTHAL GMBH (DE) 2019-03-21 — — US disclosed
US-10093691-B2 Crystallization method and bioavailability GRUNENTHAL GMBH (DE) 2018-10-09 — — US disclosed
CN-108601791-A Method for crystallising and bioavilability 格兰泰有限公司 2018-09-28 — — CN disclosed
EP-3362071-A1 CRYSTALLIZATION METHOD AND BIOAVAILABILITY Grünenthal GmbH (DE) 2018-08-22 — — EP disclosed
EP-2531200-B1 CRYSTALLIZATION METHOD AND BIOAVAILABILITY GRUENENTHAL GMBH (DE) 2017-07-12 — — EP disclosed
WO-2017049294-A1 CRYSTALLIZATION METHOD AND BIOAVAILABILITY THAR PHARMACEUTICALS, INC. (US) 2017-03-23 — — WO disclosed
US-20170022227-A1 CRYSTALLIZATION METHOD AND BIOAVAILABILITY THAR PHARMACEUTICALS, INC. (US) 2017-01-26 — — US disclosed
EP-3102611-A1 HUMANIZED BETA-AMYLOID BINDING MOLECULES AND USES THEREOF Cangene Corporation (CA) 2016-12-14 — — EP disclosed
CN-101440124-A Methods for preventing mitochondrial permeability transition CORNELL RES FOUNDATION INC (US) 2009-05-27 — — CN disclosed
CN-101214380-A Method and carrier complexes for delivering molecules to cells CORNELL RES FOUNDATION INC (US) 2008-07-09 — — CN disclosed
EP-1833571-A1 COSMETIC COMPOSITION FOR SKIN APPLICATION SUITABLE FOR RELAXING EXPRESSION WRINKLES LABO Cosprophar AG (CH) 2007-09-19 — — EP disclosed
US-20070148118-A1 Cosmetic composition for skin application suitable for relaxing expression wrinkles LABO COSPROPHAR AG (CH) 2007-06-28 — — US disclosed
WO-2006069608-A1 COSMETIC COMPOSITION FOR SKIN APPLICATION SUITABLE FOR RELAXING EXPRESSION WRINKLES LABO COSPROPHAR AG (CH) 2006-07-06 — — WO disclosed
EP-0804460-A1 CONFORMATIONALLY CONSTRAINED REVERSE-TURN LIBRARY AND METHODS RELATING THERETO MOLECUMETICS, LTD. (US) 1997-11-05 — — EP disclosed
WO-1996022304-A1 CONFORMATIONALLY CONSTRAINED REVERSE-TURN LIBRARY AND METHODS RELATING THERETO MOLECUMETICS, LTD. (US) 1996-07-25 — — WO disclosed
US-4678797-A INSECTICIDES, MITICIDES, NEMATOCIDES, FUNGICIDES, FEED UTILIZATION BAYER AKTIENGESELLSCHAFT (DE) 1987-07-07 — — US disclosed
US-4670423-A Monosilylated aminophenylethylamine derivatives, a process for their preparation, and their use for promoting growth BAYER AKTIENGESELLSCHAFT (DE) 1987-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10093691-B2 Crystallization method and bioavailability ABCG2, GYS2, PYGL SLC7A5 445/4885ITGB3 4546/4885ITGA2B 4604/4885
US-20190083407-A1 CRYSTALLIZATION METHOD AND BIOAVAILABILITY ABCG2, GYS2, PYGL SLC7A5 445/4885ITGB3 4546/4885ITGA2B 4604/4885
US-20170022227-A1 CRYSTALLIZATION METHOD AND BIOAVAILABILITY ABCG2, GYS2, PYGL SLC7A5 445/4885ITGB3 4546/4885ITGA2B 4604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.